Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

PHASE3TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 16, 2018

Primary Completion Date

November 6, 2020

Study Completion Date

November 6, 2020

Conditions
Glioblastoma
Interventions
DRUG

Trans Sodium Crocetinate plus SOC

Trans Sodium Crocetinate (TSC) plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide

OTHER

Standard of Care (SOC)

Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide

Trial Locations (13)

10029

Mount Sinai Hospital, New York

11030

North Shore University Hospital, Manhasset

29425

Scott Lindhorst, M.D., Charleston

30318

Piedmont Cancer, Atlanta

31904

John B. Amos Cancer Center, Columbus

55407

Abbott Northwestern Hospital, Minneapolis

75246

Neuro Oncology Associates, Dallas

87102

UNM Comprehensive Cancer Center, Albuquerque

90404

John Wayne Cancer Institute @ Providence Saint John's Health Center, Santa Monica

92868

University of California, Irvine

94063

Scott Peak, M.D., Redwood City

97213

Providence Portland Medical Center, Portland

07601

John Theurer Cancer Center, Hackensack

Sponsors
All Listed Sponsors
lead

Diffusion Pharmaceuticals Inc

INDUSTRY